What is the ROE (Return on Equity) of Karo Pharma this year?
The ROE of Karo Pharma this year is -0 undefined.
Karo Pharma ROE 2024
Karo Pharma ROE
-0
Ticker
KARO.ST
ISIN
SE0007464888
WKN
A14YW4
In 2024, Karo Pharma's return on equity (ROE) was -0, a 0% increase from the 0 ROE in the previous year.
Karo Pharma Aktienanalyse
What does Karo Pharma do?
Karo Pharma AB is a Swedish pharmaceutical company specializing in the manufacturing and distribution of over-the-counter drugs and health products. The company's history dates back to 1986 when it was founded as Karo Bioforskning. Over time, the company went through several restructurings and realignments until it finally became an independent company listed on the Stockholm Stock Exchange in 2017 under the name Karo Pharma AB. Karo Pharma's business model is based on a broad portfolio of over-the-counter drugs and health products tailored to the needs of consumers in different countries and for different indications. The product range includes pain relievers, cold remedies, medications for digestive disorders, and eye care products. In addition, the company also offers dietary supplements and other health products. Karo Pharma operates in three main segments: Consumer Healthcare, Prescription Pharmaceuticals, and Out-licensing. Consumer Healthcare focuses on over-the-counter drugs and health products for end consumers. Examples include VagiVital, a medication for the treatment of vaginal yeast infections, and MolluscumVital, a product for the removal of warts. In the Prescription Pharmaceuticals segment, Karo Pharma offers prescription drugs for specific indications, such as Eklira, used in the treatment of chronic obstructive pulmonary disease (COPD). The Out-licensing segment involves the licensing of products and technologies to other companies. Karo Pharma has a particular focus on the development of products based on natural active ingredients. For example, Prenoxdiazin, used for pain relief, is based on an extract from the root of peonies. Natural ingredients are preferred in the development of other products as well, to maximize their compatibility and effectiveness. Overall, Karo Pharma's portfolio includes more than 20 brands and over 100 products distributed in various countries. The company is headquartered in Stockholm and operates in several European countries, as well as in the United States and Canada. Karo Pharma emphasizes close collaboration with doctors and pharmacists to ensure that its products meet the needs of consumers optimally. In recent years, Karo Pharma has become the leading provider of over-the-counter drugs and health products in Scandinavia and now plans to expand its presence in other European countries. The company aims to strengthen its position as the leading provider of over-the-counter drugs and health products, with a focus on innovative and natural solutions, through a combination of organic growth and targeted acquisitions of companies with complementary products and technologies. Karo Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Karo Pharma's Return on Equity (ROE)
Karo Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Karo Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Karo Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Karo Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Karo Pharma stock
How has the Return on Equity (ROE) of Karo Pharma developed compared to the previous year?
The ROE of Karo Pharma has increased by 0% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Karo Pharma?
A high ROE indicates that Karo Pharma generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Karo Pharma?
A low ROE can indicate that Karo Pharma is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Karo Pharma affect the company?
A change in ROE (Return on Equity) of Karo Pharma can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Karo Pharma?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Karo Pharma?
Some factors that can influence Karo Pharma's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Karo Pharma pay?
Over the past 12 months, Karo Pharma paid a dividend of 0.27 SEK . This corresponds to a dividend yield of about 0.45 %. For the coming 12 months, Karo Pharma is expected to pay a dividend of 0.4 SEK.
What is the dividend yield of Karo Pharma?
The current dividend yield of Karo Pharma is 0.45 %.
When does Karo Pharma pay dividends?
Karo Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Karo Pharma?
Karo Pharma paid dividends every year for the past 4 years.
What is the dividend of Karo Pharma?
For the upcoming 12 months, dividends amounting to 0.4 SEK are expected. This corresponds to a dividend yield of 0.66 %.
In which sector is Karo Pharma located?
Karo Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Karo Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Karo Pharma from 5/11/2018 amounting to 0.3 SEK, you needed to have the stock in your portfolio before the ex-date on 5/4/2018.
When did Karo Pharma pay the last dividend?
The last dividend was paid out on 5/11/2018.
What was the dividend of Karo Pharma in the year 2023?
In the year 2023, Karo Pharma distributed 0 SEK as dividends.
In which currency does Karo Pharma pay out the dividend?
The dividends of Karo Pharma are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Karo Pharma
Our stock analysis for Karo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
